Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 3/20 | 0.36 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | GAA | P10253 | 3/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.32 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.32 |
| ▸ | RAD52 | P43351 | 1/20 | 0.32 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | SUV39H2 | Q9H5I1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL659593 | 0.92 | HTR7 (0.37) | FFAR4MAPTGAASMN1; SMN2ATM | |
| SCHEMBL660378 | 0.89 | FFAR4 (0.40) | FFAR4MEN1KMT2AMAP4K1 | |
| SCHEMBL658166 | 0.87 | MAPT (0.42) | MAPTGAAMEN1KMT2ARAD52 | |
| SCHEMBL659198 | 0.87 | CCR1 (0.42) | PIK3CAMAPTLMNA | |
| SCHEMBL660332 | 0.87 | DRD2 (0.39) | FFAR4LMNAPOLB | |
| SCHEMBL658811 | 0.84 | MAPT (0.36) | MAPTGAASMN1; SMN2MEN1KMT2A | |
| SCHEMBL660130 | 0.84 | GAA (0.33) | PIK3CAFFAR4MAPTGAAMEN1 | |
| SCHEMBL658597 | 0.84 | DRD2 (0.46) | MAPTGAAMEN1KMT2ALMNA | |
| SCHEMBL659567 | 0.83 | MAPT (0.44) | MAPTSMN1; SMN2ATMMEN1KMT2A | |
| SCHEMBL659005 | 0.81 | DRD2 (0.43) | MAPTGAAMEN1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8957069-B2 | Benzofuran derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-02-17 | — | — | US | disclosed |
| US-8957069-B2 | Benzofuran derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-02-17 | — | — | US | disclosed |
| US-8957069-B2 | Benzofuran derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-02-17 | — | — | US | disclosed |
| EP-2781513-A1 | Benzofuran derivatives | Takeda Pharmaceutical Company Limited (JP) | 2014-09-24 | — | — | EP | disclosed |
| EP-2406243-B1 | BENZOFURAN DERIVATIVES | TAKEDA PHARMACEUTICAL (JP) | 2014-05-07 | — | — | EP | disclosed |
| US-8288390-B2 | Benzofuran derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-10-16 | — | — | US | disclosed |
| US-8288390-B2 | Benzofuran derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-10-16 | — | — | US | disclosed |
| US-20120232096-A1 | BENZOFURAN DERIVATIVES | TSUKAMOTO TETSUYA (JP) | 2012-09-13 | — | — | US | disclosed |
| US-20120232096-A1 | BENZOFURAN DERIVATIVES | TSUKAMOTO TETSUYA (JP) | 2012-09-13 | — | — | US | disclosed |
| US-20120232095-A1 | BENZOFURAN DERIVATIVES | TSUKAMOTO TETSUYA (JP) | 2012-09-13 | — | — | US | disclosed |
| US-20120232095-A1 | BENZOFURAN DERIVATIVES | TSUKAMOTO TETSUYA (JP) | 2012-09-13 | — | — | US | disclosed |
| US-20120232095-A1 | BENZOFURAN DERIVATIVES | TSUKAMOTO TETSUYA (JP) | 2012-09-13 | — | — | US | disclosed |
| US-20120046277-A1 | BENZOFURAN DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-02-23 | — | — | US | disclosed |
| US-20120046277-A1 | BENZOFURAN DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-02-23 | — | — | US | disclosed |
| US-20100234357-A1 | Benzofuran derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-16 | — | — | US | disclosed |
| US-20100234357-A1 | Benzofuran derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120232096-A1 | BENZOFURAN DERIVATIVES | AHR, BRPF3, CBR3 | PIK3CA 3682/4885FFAR4 1079/4885MAPT 3969/4885 |
| US-20100234357-A1 | Benzofuran derivatives | AHR, BRPF3, CBR3 | PIK3CA 3682/4885FFAR4 1079/4885MAPT 3969/4885 |
| US-20120232095-A1 | BENZOFURAN DERIVATIVES | AHR, BRPF3, CBR3 | PIK3CA 3682/4885FFAR4 1079/4885MAPT 3969/4885 |
| US-20120046277-A1 | BENZOFURAN DERIVATIVES | BRPF3, BRD1, CBR3 | PIK3CA 3553/4885FFAR4 1415/4885MAPT 4353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.